A Breakthrough Organ-Scale Biology Platform for Drug Development

Organ-scale biology is defined as physiologically faithful systems that capture the structure, function, and composition of real human tissues. The NIH and FDA have funded  programs to develop organ-scale biology platforms as a means of addressing critical challenges in the drug development pipeline. However, older solutions such as organoids and on-a-chip systems cannot engineer the cellular composition of tissues, let alone the full structure, function, and patient-specific heterogeneity of human tissues. Keliomics’ technology leapfrogs current technologies by maintaining primary human tissues alive ex vivo for a minimum of 8 weeks. In this presentation, CEO Dr. Frank Lau, MD, FACS, will highlight the competitive advantages that biopharmaceutical companies can gain by incorporating Keliomics’ ex vivo organs and tumors into preclinical efficacy testing and biomarker/companion diagnostic development.

Dr. Lau previously co-founded two medical education SaaS companies, with a successful exit in 2018 when Firecracker was acquired by international publisher Wolters Kluwer Wolters. He earned his Bachelor’s in Molecular Biochemistry and Biophysics from Yale, and his M.D. with Research Honors from the University of Michigan. He has completed his plastic & reconstructive surgery residency and a stem cell research fellowship at Harvard.